P. Doug CORRECTLY (what occurs in in reality/busines) wrote:
Giving it a little more thought, it may simply be that, with the potential prospect of non-bundle reimbursement, no big provider feels like they have to take the risk of buying Triferic and using it with bundle reimbursement. With non-bundle reimbursement, it's a can't lose proposition, with bundle pricing, it gets a little dicier.
That may be all this is. A resolution to the non-bundle pricing question, either way, may be necessary before any product moves in the US
Certain products /drugs fall squarely under the bundled process. The outlier Rob mentioned in the CC may or may not have. However, a post was provided earlier with a phone number to a consulting group regarding these issues. Rockwell needs to get in touch with experts in this arena. Hire them and get an answer. My take is that triferic falls under the bundled process, but as a novel drug w/ a new mechanism to deliver trifer/other reasons - triferic may still qualify for transitional add-on payment.
another poster was saying that...I was trying to find precedence with another drug that CMS granted transition add-on payment at 106% vs being part of the bundled payment. I am thinking DaVita is ready to move forward, but wants Triferic to be an outlier for two years at 106% versus trying to make Triferic part of the bundled payment. It is worth a shot and RMTI would be criticized for not taking it...if not, then Triferic would fall under the bundled payment system.
Anyone know which drug/co. was being referenced in the CC?
Patients still receiving Triferic, Hemoglobin & ESA managed as expected, dialysis providers to see economic benefit, pilots ongoing, int'l deals secured. THIS things trades like a BIO...oh...it is!
Expect news on the CMS transitional add-on payment soon. IV Iron overload still an issue AND VERY Expensive!!!
Thanks for the recap MAHA. When it from $5 to $10, I thought I missed nearly 5 points. Now I can buy while the shorts cover. I'm looking long term. Great Deal for RMTI in China and other markets. CMS paved the path already for transitional add-on payments, this will come around soon.
Good to see you back MAHA..read your other post as well!! Great recap!
HUGE FOR CHINA, HUGE FOR ROCKWELL.
Plus we know the backgroung of that report AND THE MANY INCORRECT ASSERTIONS AND FACTS!!! Just Like YOU!!!!
* Medicare cuts will benefit Rockwell
* The sell-off is a great opportunity for anyone to buy that missed the initial upward trend.
* The market is completely neglecting the stock because they have no idea how to value it appropriately.
* The company is bringing a drug onto the market with no side effects to compete with drugs that are black boxed.